Compare Nerdwallet Inc (NRDS) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nerdwallet Inc vs BIO-TECHNE Corp — how do they compare? Nerdwallet Inc trades at $9.78 (market cap $627.09M), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp is far larger — about 17.9× Nerdwallet Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals.
| NRDS | TECH | |
|---|---|---|
Market Cap | $627.09M | $11.24B |
Sector | Financials | Health |
52-Week High | $15.93 | $72.29 |
52-Week Low | $7.58 | $43.31 |
Enterprise Value | $541.39M | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NerdWallet (NRDS) trades at $9.91, up 12.1% in the past 24 hours, with a bullish technical signal from moving averages. The company shows strong revenue growth from $539M in 2022 to $837M in 2025, with net income turning positive to $48.7M. Recent Q2 2026 earnings missed expectations at $0.07 per share versus $0.0934 expected, though Q1 and Q4 2025 beat estimates. Valuation metrics appear attractive with a P/E of 10.9 and P/S of 0.82.
The outlook remains positive with analyst consensus favoring Buy ratings (66.7%) and projected 27.9% upside potential. Key risks include execution challenges in shifting from SEO-dependent referrals and competitive pressure in financial guidance markets. Strong cash flow generation and improving profitability support the bullish case, though investors should monitor quarterly earnings consistency.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nerdwallet Inc
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
